“Specialty Drugs”

31 result(s)
Specialty
Research published by Coram shows that helping patients transition to at-home or ambulatory center infusion treatments can be beneficial to both patients and payors. More
Briefing
Specialty
Key drugs to watch for in the specialty pharmacy pipeline Q4 2018–Q1 2019 More
Specialty Report
Care Management
Oncologists need to take in an enormous amount of information to provide their patients with the most up-to-date treatment. CVS Specialty is partnering with NCCN to provide... More
Briefing
Cost Management
CVS Caremark’s QALY-based program aims to bring rationality to drug pricing using comparative effectiveness research and cost-effectiveness analysis, and get manufacturers to set... More
Commentary
Care Management
Cancer therapy is evolving and new treatments are being developed at an almost breakneck pace. To help better manage care and costs for oncology, CVS Health has developed an... More
Briefing
Specialty
CVS Health’s three-tier specialty formulary design separates the increasingly more expensive specialty therapies into three distinct copay or coinsurance categories. Paired with... More
Briefing
Specialty
PAH is a rare, life-threatening disease, which is incurable. It is difficult to manage and to help ensure the longest survival and best possible quality of life, members need... More
Briefing
Drug Pipeline
When the FDA approves a “supplemental indication” for a drug already on the market — permitting it to be used for new conditions or stages of a disease, or additional patient... More
Briefing
Cost Management
Our formulary strategies effectively leverage competition in the pharmaceutical market to help reduce costs and trend for PBM clients. More
Video
Drug Pipeline
Scientific developments are altering the pace and focus of specialty drug development, while regulatory changes are shortening approval times. This poses new challenges for payors... More
Briefing